| CTRI Number |
CTRI/2024/03/064832 [Registered on: 27/03/2024] Trial Registered Prospectively |
| Last Modified On: |
21/03/2024 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Observational |
|
Type of Study
|
Cross Sectional Study |
| Study Design |
Other |
|
Public Title of Study
|
Relationship of serum LDH With fetomaternal outcome in pre eclampsia |
|
Scientific Title of Study
|
Association of serum lactate dehydrogenase with fetomaternal outcome in pre eclampsia- A cross sectional study |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr KHUSHBOO CHAURASIA |
| Designation |
JUNIOR RESIDENT |
| Affiliation |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL |
| Address |
ROOM NO 1178, Department of OBG, ROHILKHAND MEDICAL COLLEGE AND HOSPITAL, PILIBHIT BYPASS ROAD, BAREILLY
Bareilly UTTAR PRADESH 243006 India |
| Phone |
09755686239 |
| Fax |
|
| Email |
khushboochaurasia25@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
DR LATA AGRAWAL |
| Designation |
PROFESSOR |
| Affiliation |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL |
| Address |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL, PILIBHIT BYPASS ROAD, BAREILLY
Bareilly UTTAR PRADESH 243006 India |
| Phone |
9557033100 |
| Fax |
|
| Email |
drlataagrawal.la@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
DR KHUSHBOO CHAURASIA |
| Designation |
JUNIOR RESIDENT |
| Affiliation |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL |
| Address |
ROOM NO 1178, Department of OBG ROHILKHAND MEDICAL COLLEGE AND HOSPITAL, PILIBHIT BYPASS ROAD, BAREILLY
Bareilly UTTAR PRADESH 243006 India |
| Phone |
09755686239 |
| Fax |
|
| Email |
khushboochaurasia25@gmail.com |
|
|
Source of Monetary or Material Support
|
| Rohilkhand medical college and hospital |
|
|
Primary Sponsor
|
| Name |
Department of obstetric and gynaecology |
| Address |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL, PILIBHIT BYPASS ROAD, BAREILLY |
| Type of Sponsor |
Private medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Khushboo Chaurasia |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL |
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL, PILIBHIT BYPASS ROAD, BAREILLY Bareilly UTTAR PRADESH |
9755686239
khushboochaurasia25@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee, RMCH, Bareilly, U.P. |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: O149||Unspecified pre-eclampsia, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
20.00 Year(s) |
| Age To |
40.00 Year(s) |
| Gender |
Female |
| Details |
1.Singelton pregnancy.
2.Pregnant women at more than 28 weeks of period till term of gestation.
3.Women willing for our participation as per protocol.
|
|
| ExclusionCriteria |
| Details |
1.Patient with history of diabetes, renal disease, chronic hypertension, liver disease, chronic lung disease, connective tissue disorders, seizure, DIC, stroke, smoking, alcoholism, any hepatotoxic drugs, thyroid disorder and UTI.
2.Patient with molar pregnancy, gestational diabetes mellitus. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Relationship of LDH in pre eclampsia |
1 year |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Maternal mortality, morbidity and fetal outcome |
1 year |
|
|
Target Sample Size
|
Total Sample Size="147" Sample Size from India="147"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
07/04/2024 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Preeclampsia is described as a pregnancy specific syndrome that can affect every organ system of the body. It is defined as new onset hypertension and either proteinuria or other signs of end organ damage after 20 weeks of gestation in a previously normotensive normoproteinuric woman. It involves multisystem disorder which includes thrombocytopenia, renal dysfunction, hepatocellular necrosis, central nervous system pertubations or pulmonary oedema. It is a syndrome where mother and fetus both are affected. Maternal syndrome includes hypertension, intra uterine growth retardation, oliguria, HELLP syndrome, seizure, oedema, proteinuria, pleural effusion, pulmonary oedema, thrombocytopenia, disseminated intravascular coagulation and hemoconcentration. Fetal syndrome includes preterm delivery, intra uterine fetal death. Young and nulliparous are more vulnerable to develop preeclampsia while older women have a greater risk for developing chronic hypertension with superimposed preeclampsia. It is well proven that it is primarily a disorder of first pregnancy. Gestational hypertension is a transient hypertension which develops after 20 weeks of gestation in a previously normotensive women with no proteinuria or no signs of endorgan damage. Preeclampsia when complicated with Grand Mal Seizures (Generalized Tonic Clonic convulsions) and/or coma is called Eclampsia. The American College of Obstetricians and Gynaecologists describes four types of hypertensive diseases: 1. Preeclampsia and eclampsia syndrome 2. Chronic hypertension due to other causes 3. Preeclampsia superimposed on chronic hypertension 4. Gestational hypertension
In normal pregnancy there is invasion of the endovascular trophoblasts into the wall of the spiral arterioles of the uteroplacental bed.Endovascular trophoblasts invades up to decidual segments in the first trimester(10-12 wks) and another wave of trophoblasts invades up to the myometrial segments in second trimester (16-18 wks), thus the endothelial lining and muscular arterial walls is replaced by fibrinoid formation as a result spiral arterioles becomes torturous,distended and funnel shaped which in turn transforms the spiral arterioles into a low resistance, low pressure, high flow system.In Preeclampsia there is a failure of second wave of endovascular trophoblast migration and reduction of blood supply to the fetoplacental unit.There are many theories which explain the pathophysiology of preeclampsia.One of the accepted hypothesis is abnormal placentation with incomplete secondary wave of trophoblastic invasion which leads to reduced uteroplacental blood flow, placental ischaemia and hypoxia. Preeclampsia is seen in 5-8% of all pregnancies. It can virtually affect every organ system.It can be divided into early onset i.e., <34 wks; late onset i.e., >= 34 wks; Preterm onset i.e., <37 wks; Term onset i.e., >=37 wks. Lactate Dehydrogenase is a marker which is raised in Preeclampsia. Its levels are several times higher inside the cell as compared to plasma. It is an intracellular enzyme belongs to 2-hydroxy acid oxidoreductase group which is responsible for interconversion of Pyruvate and Lactate in the cells during Glycolysis which is the major energy pathway in the placenta. In preeclampsia there is cell damage which results in leakage of enzyme into the circulation causing high serum levels.
|